Palatin Technologies Inc.

r. Spana, co-founder of Palatin, has been our chief executive officer and president since June 14, 2000. He has been a director of Palatin since June 1996 and has been a director of our wholly-owned subsidiary, RhoMed Incorporated, since July 1995. From June 1996 through June 14, 2000, Dr. Spana served as an executive vice president and our chief technical officer. From June 1993 to June 1996, Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. Through his work at Paramount Capital Investments and The Castle Group, Dr. Spana co-founded and acquired several private biotechnology firms. From July 1991 to June 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb, a publicly traded pharmaceutical company, where he was involved in scientific research in the field of immunology. Dr. Spana is a director of AVAX Technologies, Inc., a publicly-held life science company. Dr. Spana received his Ph.D. in molecular biology from The Johns Hopkins University and his B.S. in biochemistry from Rutgers University.

Dr. Sharma is vice president and chief scientific officer at Palatin Technologies, Inc., and has been with the company since 1995. He is the inventor of Palatin's proprietary, MIDAS drug discovery platform. Dr. Sharma is a peptide chemist with more than 18 years of experience in the areas of peptide research, drug design and discovery. Prior to joining Palatin, Dr. Sharma was a research scientist in the research group of Prof. Victor J. Hruby, of the University of Arizona, Tucson from 1988 to 1994. From 1984 to 1988, Dr. Sharma was a scientist in the research group of Prof. Robert Schwyzer, of the Swiss Federal Institute of Technology, Zurich (ETH-Zurich), Switzerland. Dr. Sharma has several issued patents and patent applications pending and is the author of over 50 publications. He earned his Ph.D. in chemistry from the Central Drug Research Institute in Lucknow, India.

Dr. Hallam joined Palatin in May, 2005 as executive vice president of research & development. He possesses over 20 years of drug discovery and development experience within the pharmaceutical industry. From 1996 to 2005, Dr. Hallam held key senior management leadership positions within AstraZeneca R&D, including vice president of biologics based out of the UK, vice president of respiratory and inflammation research based in Sweden and vice president of medical affairs within the US. During this time, Dr. Hallam developed and implemented programs to broaden the firm’s portfolio of products, established strategic partner relationships and defined new discovery strategies. From 1985 to 1995, Dr. Hallam served at progressively senior management positions within Smith Kline & French Research, Glaxo Group Research and Roche Research. His accomplishments include development of numerous drug candidates for a variety of indications, including asthma, rheumatoid and osteo-arthritis, multiple sclerosis and transplant rejection. Dr. Hallam joined the pharmaceutical industry after a post-doctoral fellowship at the Physiological Laboratory, University of Cambridge, UK. He earned his Ph.D. in biochemistry from the University of London and his B.Sc. from the University of Leeds.

John Prendergast, Executive Chairman and CEO, is a biopharmaceutical executive who has been involved in the financing and corporate development of early to mid-stage biotechnology companies over the past 15 years. He is a co-inventor of Antyra's Phenogenix and Proteome Panning? technology modules. He is a co-founder and currently serves on the boards of Avigen Inc., Palatin Technologies and Avax Technologies. From 1991-1996, Dr. Prendergast was Managing Director of the Castle Group, a New York-based merchant bank where he was responsible for the identification and evaluation of products and technologies for the formation and development of a range of venture start-ups. He is currently the President of SummerCloud Bay Inc., a consulting practice specializing in these activities.

Christopher Steidle, M.D., attended Tulane University and graduated Magna Cum Laude with a B.S. degree in Parasitology. He received his M.D. degree in 1983 from the University of Virginia School of Medicine where he gained extensive research experience, including studies conducted through the National Institutes of Health. In 1989, he completed his general surgical training in urology at Indiana University Hospital where he had become chief resident. He has served as a visiting scientist at Eli Lilly in Indianapolis, Indiana, where his work centered on the pharmacologic receptor identification in the genitourinary tissues of various species, with special emphasis on the identification of serotonin receptor sub-types. Currently, Chris works in his own practice in Fort Wayne, Indiana and is a Clinical Associate Professor of Urology at the Indiana University School of Medicine. He has been actively involved in clinical research since 1989 specializing in male and female sexual dysfunction as well as urinary incontinence, prostate cancer and infectious diseases. He is the author of two books, The Impotence Sourcebook and testosterone: a user's manual. You can now contact Dr. Steidle for appointments through his own website at www.neiurology.com.

Dr. Michael A. Perelman is the Co-Director of the Human Sexuality Program, Payne Whitney Clinic of the New York Presbyterian Hospital in New York City. He has been affiliated with this program, founded by his late mentor Dr. Helen S. Kaplan, for over twenty-five years. He holds a joint appointment on the faculty in both Psychiatry and in Urology at Weill Medical College of Cornell University. He also is the Senior Consulting Psychologist/Sex Therapist at the NY Center for Human Sexuality, holding an appointment in the Department of Urology, Columbia University, Columbia Presbyterian Medical Center. Additionally, he is the Senior Consulting Sex Therapist to the Department of Urology at Greenwich Hospital. A National Institute of Mental Health Fellow, he received his MS, M.Phil., and Ph.D. degrees in clinical psychology from Columbia University, writing the first sex therapy doctoral dissertation in Columbia's history. Dr. Perelman was Chief Intern in Medical Psychology at Duke University Medical Center. He was a 1974 Postdoctoral Fellow in sex therapy at Cornell's Human Sexuality Program of the Payne Whitney Clinic, New York Presbyterian Hospital. Dr. Perelman is a New York State certified psychologist and is listed in the National Register of Health Service Providers in Psychology. He maintains an independent practice in Manhattan, specializing in sex and marital therapy. He is certified by the American Association of Sex Educators, Counselors and Therapists (AASECT) as a sex educator, therapist and supervisor. He has served on several boards of directors including The Society for Sex Therapy and Research (SSTAR) and AASECT. He is a member of over twenty other professional societies, including the American Psychological Association, the American Urological Association (AUA), the Society for the Scientific Study of Sex (SSSS), the International Society for Sexual and Impotence Research (ISSIR), and the International Society for Study of Women's Sexual Health (ISSWSH). He has served as consulting editor for a variety of professional journals, currently including the Journal of Sex and Marital Therapy. He co-authored Late Bloomers, published by Macmillan, with Carol Colman. Dr. Perelman has published a number of chapters in sex therapy texts and has presented numerous papers at professional meetings, as well as having his work in sex and marital therapy frequently featured in the media.

Robert A. Kloner, MD, PhD, is Professor of Medicine in the Cardiovascular Division, Keck School of Medicine of the University of Southern California, in Los Angeles. He is also Director of Research at the Heart Institute of Good Samaritan Hospital in Los Angeles and attending cardiologist at Los Angeles County/University of Southern California Medical Center. Dr Kloner received his MD in the honors program in medical education and his PhD from Northwestern University The Feinberg School of Medicine in Chicago, Illinois, and is a member of the Alpha Omega Alpha honor society. He completed an internship and residency in internal medicine at Brigham and Women's Hospital (formerly Peter Bent Brigham Hospital) in Boston, Massachusetts. Additional training included clinical and research fellowships in medicine and cardiology at Harvard Medical School and Brigham and Women's Hospital. He served as Assistant and then Associate Professor of Medicine at Harvard Medical School and as an attending cardiologist at Brigham and Women's Hospital. There he received the Established Investigator Award of the American Heart Association (AHA). Dr Kloner is a fellow of the American College of Cardiology, an inaugural fellow of the Council on Basic Cardiovascular Sciences of the AHA, and was elected to the American Society of Clinical Investigation. A frequent contributor to the medical and scientific press, Dr Kloner has contributed 500 original papers, 196 chapters or monographs, and 410 abstracts. He is the author and editor of 18 medical texts, including Cardiovascular Trials Reviews (10 editions), The Guide to Cardiology, Stunned Myocardium, Ischemic Preconditioning, VIAGRA, and Heart Disease & Erectile Dysfunction and 3 novels titled The Beta Virus, Mind Cure, and The Deity Genes. Among his editorial responsibilities, Dr Kloner serves as Associate Editor of the Journal of Cardiovascular Pharmacology and Therapeutics and the International Journal of Impotence Research and is on the editorial boards of the Journal of the American College of Cardiology, Circulation, American Journal of Cardiology, American Journal of Geriatric Cardiology, Journal of Molecular and Cellular Cardiology, Heart, Heart Disease, Basic Research in Cardiology, and Regenerative Medicine. Among his many career distinctions, Dr Kloner has been listed in Who's Who in America and The Best Doctors in America and in 2002 was identified by the Institute for Scientific Information as ISI Highly cited.com; one of the world's most highly cited scientific authors.

Mr. Hull has been a director since September 2005. Mr. Hull has over three decades of experience in the field of sales and marketing. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company in October 1987 and is currently Senior Vice President, Pharmaceuticals. Prior to his current position, he served in the R&D organization of GlaxoSmithKline as Vice President and Worldwide Director of Therapeutic Development and Product Strategy-Neurology and Psychiatry. Prior to that, he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome Inc. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978. Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.

Dr. Taber has been a director since May 2001. Dr. Taber began his career in the pharmaceutical industry in 1962, holding a succession of positions within Schering Corporation’s biological research group before leaving in 1982 as a director of biological research. He has also held a number of increasingly important positions with DuPont Pharmaceuticals and the DuPont Merck Pharmaceutical Company, including director of pharmaceutical research, director of pharmaceutical and biotechnology research, vice president of pharmaceutical research and vice president of extramural research and development. From 1994 to 1998, Dr. Taber held the position of senior vice president of research and development at Synaptic Pharmaceuticals Corporation before founding Message Pharmaceuticals, Inc. in 1998 serving as president and chief executive officer until 2000. Dr. Taber earned his Ph.D. in pharmacology from the Medical College of Virginia.